Physician profile
Vitor Weinman
NPI 1295831360
$758.35
in general payments reported to CMS, 2019-2025
14 companies · $66.04 in 2025
The $66.04 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $226 · 2021: $129 · 2022: $13.96 · 2023: $123 · 2024: $52.57 · 2025: $66.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $235.52 | 2019-2021 | |
| Amgen INC. | $219.38 | 2020-2023 | Otezla |
| Leo Pharma INC. | $61.71 | 2019-2020 | |
| Revance Therapeutics, INC. | $52.57 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $25.97 | 2019-2025 | Xtrac |
| Vyne Pharmaceuticals INC. | $24.14 | 2020 | |
| Genzyme Corporation | $23.38 | 2025 | |
| Merz North America, INC. | $22.91 | 2019 | |
| Almirall LLC | $20.61 | 2025 | Seysara |
| Merck Sharp & Dohme LLC | $17.59 | 2019 | |
| Celgene Corporation | $17.50 | 2019 | |
| Galderma Laboratories, L.P. | $15.36 | 2023 | |
| Journey Medical Corporation | $13.96 | 2022 | |
| Organon LLC | $7.75 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitor Weinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.